EFFICACY OF COMPOUNDING TOPICAL TACROLIMUS FOR SUBEPITHELIAL CORNEAL INFILTRATES TREATMENT
Instituto Oftalmológico Fernández-Vega, Oviedo (Spain)

Purpose
To determine the efficacy of compounding topical tacrolimus treatments for SEIs after Adenovirus keratoconjunctivitis.

Material and Methods
The parameters measured were:
- The visual acuity before and after treatment
  • Measured by LogMAR
- Intraocular pressure before, during and at the end of treatment
  • Measured by Perkin's tonometer
- Treatments before tacrolimus
- Result of SEIs after treatment

The data were analyzed in the IBM Microsoft SPSS® Statistics version 22.0.

Results
- Tacrolimus 0.03% eye drops twice daily
- Tacrolimus 0.2% ointment once daily

| DEMOGRAPHIC | 63 patients (99 eyes) | 57.1% with bilateral affection. | Middle age: 46.85 years (SD=14.93). |
| TREATMENT | 37 patients (58.7%) tacrolimus 0.03% eye drops | 26 patients (41.3%) were treated with Tacrolimus 0.02% ointment and |
| FOLLOW-UP | The mean duration of treatment was 105 days (rank: 55-199) | The mean follow up 112.5 days (57.25-426.75) |
| SEIS | - Decrease in the SEIs 56.56% of the eyes - In 19.19% disappeared the SEIs |
| VISUAL ACUITY | In 17 eyes (53.1%) increment with a mean of 0.331 (rank: 0.1-0.7) |

Epidemic keratoconjunctivitis (EKC) is a highly contagious infection that mainly involves the surface of the eye. Keratitis may appear, approximately 10 days after the onset of the follicular conjunctivitis, with the formation of sub-epithelial corneal infiltrates (SEIs), usually bilaterally and asymmetric. The SEIs have the potential to cause significant ocular morbidity, with reduced vision, photophobia, glare, halos, and foreign body sensation, and can persist for months or years after the initial infection. Tacrolimus has demonstrated effectiveness in this ocular pathology in some studies.

Discussion

Topical tacrolimus eye drops and ointment, which are compounding in the Pharmacy Service, seems to be an effective treatment in SEIs after adenovirus keratoconjunctivitis.